Prosecution Insights
Last updated: November 04, 2026

Mineralys Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Mineralys Therapeutics Inc. holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This matter is assigned to 1 distinct art unit, indicating that the company's current intellectual property efforts are focused on a specific technical division within the biotechnology sector.

The prosecution involves 1 distinct examiner, NESTOR, DONNA MICHELLE. As the busiest examiner for the portfolio, NESTOR, DONNA MICHELLE is currently managing 1 busiest examiner pending office action. This 1 pending action represents the entirety of the company's active workload at the patent office, which suggests a focused prosecution strategy.

Practitioners can focus their efforts on the 1 pending office action and the specific examination style of NESTOR, DONNA MICHELLE. Because the portfolio is concentrated in 1 distinct art unit with 1 distinct examiner, the firm can develop a targeted approach. This allows for a deep focus on the technical requirements of the Biotechnology & Pharmaceuticals area as they apply to the 1 pending office action currently under review.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
NESTOR, DONNA MICHELLE 1 58.1% +41.6%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18250402 CYP11B2 BETA HYDROXYLASE INHIBITORS FOR HYPERTENSION NESTOR, DONNA MICHELLE 88d overdue

Top Art Units

Art UnitApps
1627 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18250402 CYP11B2 BETA HYDROXYLASE INHIBITORS FOR HYPERTENSION NESTOR, DONNA MICHELLE 1627 §103 Final Rejection 88d overdue Pending Apr 25, 2023

Managing Mineralys Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Mineralys Therapeutics Inc. have?

Mineralys Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Mineralys Therapeutics Inc. applications?

Donna Michelle Nestor has the most, with 1 of Mineralys Therapeutics Inc.'s pending office actions.

What technology area are Mineralys Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month